Celldex Therapeutics, Inc. (CLDX) SEC filings

CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30

$28.83+0.30 (+1.05%)

Close on Nov 13, 2026Market cap $2.26BP/E –Yield –

SEC filings

40 of Celldex Therapeutics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 5, 2026	Nov 5, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Sep 22, 2026	Sep 22, 2026	SEC EDGAR
Current report	8-K	Aug 6, 2026	Aug 6, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Jul 10, 2026	Jul 15, 2026	SEC EDGAR
Current report	8-K	Jun 25, 2026	Jun 26, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 7, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 7, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 25, 2026	Apr 29, 2026	SEC EDGAR
Current report	8-K	Apr 1, 2026	Apr 2, 2026	SEC EDGAR
Current report	8-K	Feb 25, 2026	Feb 25, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Feb 25, 2026	SEC EDGAR
Current report	8-K	Nov 10, 2025	Nov 10, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 10, 2025	SEC EDGAR
Current report	8-K	Aug 19, 2025	Aug 19, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Aug 7, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Jun 5, 2025	Jun 6, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 8, 2025	SEC EDGAR
Current report	8-K	May 8, 2025	May 8, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 5, 2025	Apr 21, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Feb 27, 2025	SEC EDGAR
Current report	8-K	Feb 27, 2025	Feb 27, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 6, 2024	SEC EDGAR
Current report	8-K	Nov 6, 2024	Nov 6, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 8, 2024	SEC EDGAR
Current report	8-K	Aug 8, 2024	Aug 8, 2024	SEC EDGAR
Current report	8-K	Jun 13, 2024	Jun 14, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 6, 2024	SEC EDGAR
Current report	8-K	May 6, 2024	May 6, 2024	SEC EDGAR
Proxy statement	DEF 14A	Jun 13, 2024	Apr 25, 2024	SEC EDGAR
Current report	8-K	Feb 28, 2024	Mar 1, 2024	SEC EDGAR
Annual report	10-K	Dec 31, 2023	Feb 26, 2024	SEC EDGAR
Current report	8-K	Feb 26, 2024	Feb 26, 2024	SEC EDGAR
Current report	8-K	Nov 7, 2023	Nov 8, 2023	SEC EDGAR
Current report	8-K	Nov 5, 2023	Nov 6, 2023	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2023	Nov 2, 2023	SEC EDGAR
Current report	8-K	Nov 2, 2023	Nov 2, 2023	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2023	Aug 8, 2023	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Celldex Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-15 reverse split on Feb 11, 2019
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CLDX.

Compare: CLDX vs AVTX · CLDX vs ABPO · CLDX vs ARTV · CLDX vs PVCT · CLDX vs IMA

Company	Revenue	Growth
CLDX	$158.00K	-93.9%
AVTX	–	–
ABPO	–	–
ARTV	–	–
PVCT	–	–
IMA	–	–

Company

Next earnings (est.): Feb 24, 2027, after close
Exchange: Nasdaq
Industry: In Vitro & In Vivo Diagnostic Substances
Fiscal year ends: December 31
Employees: 198
Held by institutions: 100.0%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 744218

Advertisement
300 × 250

See a number that looks wrong?